Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Systematic review comparing LABA, olodaterol, and indacaterol: limitations

Authors Donohue J

Received 23 September 2014

Accepted for publication 29 September 2014

Published 5 December 2014 Volume 2014:9(1) Pages 1331—1335

DOI https://doi.org/10.2147/COPD.S74766

Checked for plagiarism Yes

Editor who approved publication: Dr Richard Russell


James F Donohue

Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, Chapel Hill, NC, USA
 

Dear editor

Roskell et al present a systematic review comparing the long-acting beta2 agonists (LABA), olodaterol, and indacaterol in the July edition of the International Journal of Chronic Obstructive Pulmonary Disease.1 The end-points compared for the two LABAs were: change from baseline in trough forced expiratory volume in 1 second (FEV1) at week 12; quality of life analyzed by change from baseline in St George’s Respiratory Quotient (SGRQ; total score and proportion of responders) at week 12; transition dyspnea index (TDI), analyzed by change from baseline at week 12; use of rescue medication, analyzed by change from baseline in average number of puffs per day; and proportion of patients experiencing at least one exacerbation, analyzed in trials with a treatment duration of 24 weeks or longer reporting data for this outcome. The authors conclude that olodaterol and indacaterol have similar efficacy in patients with COPD. 

Read the original article 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]